Skip to main content
. 2019 Nov 1;10:1157. doi: 10.3389/fneur.2019.01157

Table 1.

Comparison among CRION, RION, and MS-ON patients.

CRION RION MS-ON P-value (Mann-Whitney U test)
CRION vs. RION CRION vs. MS-ON
n 7 11 13
Sex F:M 5:2 6:5 11:2 0.4* 0.4*
Age of onset (y)
 Mean ±SD (min–max) 29.8 ± 13.7 (20.3–55.6) 30.2 ± 13.9 (7.6–56) 30.9 ± 5.4 (24–39) 0.9 0.4
Disease duration (y)
   Mean ± SD 8.5 ± 6.1 10.4 ± 7.2 12 ± 4 0.5 0.2
   Median (range) 6.70 (1.6–17.3) 9.3 (4.3–30.4) 10.3 (7.5–20.2)
Time to recurrence (m)
   Median (range) 9 (2–81.3) 14 (1.25–98.8) 11 (1.7–231) 0.9 0.7
Number of ON attacks/patient
   Mean ± SD 4.4 ± 3.4 3.1 ± 2.2 1.8 ± 0.7 0.5 0.046
   Median (range) 4 (1–11) 2 (1–9) 2 (1–3)
Simultaneous bilateral ON attacks; n patients (%) 6 (85.7) 5 (45.5) 2 (15.3) 0.1* 0.004*
>1 episode of ON n (%) 6 (85.7) 11 (100) 9 (69) 0.4* 0.4*
Steroid dependency; n (%) 7 (100) 0 0 0.000* 0.000*
VA after the first episode
   Mean ± SD 0.4 ± 0.2 0.6 ± 0.2 0.7 ± 0.3 0.069 0.000
   Median (range) 0.5 (0.1–0.6) 0.6 (0.3–0.8) 0.7 (0.3–1)
VA at last follow-up
   Mean ± SD 0.5 ± 0.2 0.8 ± 0.1 0.9 ± 0.1 0.003 0.000
   Median (range) 0.5 (0.1–0.7) 0.8 (0.6–1) 1 (0.6–1)
Last EDSS
   Mean ± SD 2 ± 0.8 1 ± 0.7 2.6 ± 1.5 0.035 0.4
   Median (range) 2 (1–3) 1 (0–2) 2.5 (0–5.5)
OCB IgG; n (%) 1 (14.3) 1 (9.1) 12 (92.3) 0.6* 0.001*
MOG-Ab+; n (%) 4 (57.1) 1 (9.1) 0 0.047* 0.007*
AQP4-Ab+; n (%) 0 0 0 NA NA
Abnormal orbital MRI; n (%) 4 (57.1) 0 0 0.011* 0.007*
Abnormal brain MRI; n (%) 0 2 (18.2) 13 (100) 0.4* 0.000*
Abnormal spinal MRI; n (%) 0 2 (18.2) 6 (46.2) 0.4* 0.022*
Number of treatments; n
   Mean ± SD 2.2 ± 1.1 0.5 ± 0.9 2 ± 1.4 0.003 0.6
   Median (range) 2 (1–4) 0 (0–3) 2 (1–4)
Treatment; n patients (%) 4 (57.1) 2 (18.2) 9 (69.2) 0.1* 0.4*
Last treatment (n, %)
   None 3 (42.9) 9 (81.8) 1 (7.7)
   AZA 1 (9.1)
   MFM 1 (14.2)
   RTX 3 (42.8) 1 (9.1)
   Any DMT 12 (92.3)
*

Fisher exact test.

n, number; SD, standard deviation; F, female; M, male; y, years; m, months; ON, optic neuritis; BON, bilateral optic neuritis; VA, visual acuity; EDSS, Expanded Disability Status Scale; OCB, oligoclonal bands; AQP4-Ab, aquaporin-4 antibody; MOG-Ab, myelin oligodendrocyte glycoprotein antibody; AZA, azathioprine; MFM, mycophenolate mofetil; RTX, rituximab; IVIG, intravenous immunoglobulins; DMT, disease-modifying treatment; NA, not applicable. Values in bold when p < 0.05.

HHS Vulnerability Disclosure